Table 2.
Published PKIU studies comparing haplo-SCT with chemotherapy alone in adult and pediatric AML cases.
| Author, Yr, Ref. | Pts (No.) | Diagnosis | Disease status | Treatment modality | Conditioning regimen | relapse | NRM | LFS | OS | Prospective study |
|---|---|---|---|---|---|---|---|---|---|---|
| Huang XJ, et al. ( 5 ) | 58 | Inter/high-risk | CR1 | Haplo-SCT | MAC | 12% at 4yr * | 0% at 4yr | 74% at 4yr * | 78% at 4yr * | Yes |
| 74 | Inter/high-risk | CR1 | Chemotherapy | NA | 58% at 4yr | 12% at 4yr | 44% at 4yr | 55% at 4yr | ||
| Zhu HH, et al. ( 7 ) | 40 | High-risk | CR1 | Haplo-SCT | MAC | 21% at 5yr ** | NA | 62% at 5yr ** | 72% at 5yr ** | Yes |
| 29 | High-risk | CR1 | Chemotherapy | NA | 79% at 5yr | NA | 20% at 5yr | 27% at 5yr | ||
| Lv M, et al. et al. ( 53 ) | 78 | Inter-risk | CR1 | Haplo-SCT | MAC | 12% at 3 yr # | 15% at 3yr | 73% at 3 yr # | 81% at 3 yr # | Yes |
| 69 | Inter-risk | CR1 | Chemotherapy | NA | 49% at 3 yr | 3% at 3yr | 47% at 3 yr | 54% at 3 yr | ||
| Hu GH, et al. ( 55 ) | 27 | High-risk | CR1 | Haplo-SCT | MAC | 18% at 5yr ## | HR=0.238 | 87% at 5yr ## | 83% at 5yr | No |
| 28 | High-risk | CR1 | Chemotherapy | NA | 50% at 5yr | P=0.032 | 62% at 5yr | 71% at 5yr | ||
| Xue YJ, et al. ( 54 ) | 33 | Inter-risk | CR1 | Haplo-SCT | MAC | 15% at 3yr † | NA | 82% at 3yr ‡ | 85% at 3yr | No |
| 47 | Inter-risk | CR1 | Chemotherapy | NA | 33% at 3yr | NA | 67% at 3yr | 86% at 3yr |
PKIU, Peking University Institute of Hematology; MSDT, human leukocyte antigen-matched sibling donor transplantation; haplo-SCT, haploidentical stem cell transplantation; Yr, year; Ref., reference; No., number; aGVHD, acute graft-versus-host disease; NRM, nonrelapse mortality; LFS, leukemia-free survival; OS, overall survival; GRFS, GVHD and relapse-free survival; pre-MRD, pretransplantation minimal residual disease; Ad, advanced disease; MA, myeloablative; G-PB, granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood harvests; G-BM, G-CSF simulated bone marrow harvests; NA, not available.
*P<0.01 for relapse, LFS and OS compared between haplo-SCT and chemotherapy.
**P<0.01 for relapse, LFS and OS compared between haplo-SCT and chemotherapy.
#P<0.001 for relapse, LFS and OS compared between haplo-SCT and chemotherapy.
##P<0.05 for relapse and LFS compared between haplo-SCT and chemotherapy.
†P=0.059.
‡indicate event-free survival.